Sun Pharma stock: Results are due October 29 for Sun Pharma stock

Published on 10/16/2026 at 17:05 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Sun Pharma's trailing P/E was 34.89 on October 16, 2026. Sun Pharma stock costs INR 1,758.80 on October 16, 2026, down 0.29 percent on NSE.

Valuation and trading frame

A board meeting is scheduled for October 29, 2026 to consider quarterly results.
Sun Pharma's trailing P/E stood at 34.89 on October 16, 2026.
Sun Pharma stock closed at INR 1,758.80 on NSE on October 16, 2026, down 0.29 percent from INR 1,764.00.
Market capitalization was INR 4.2 trillion and the 52-week high was INR 2,046.90 on October 16, 2026.

Sun Pharma, INE044A01036, Illustration mit AI erstellt.

Sun Pharma's calendar points to October 29, 2026, when its board is scheduled to consider quarterly results, according to The Economic Times on October 16, 2026. Sun Pharmaceutical Industries Limited is identified by ISIN INE044A01036. Sun Pharma stock closed at INR 1,758.80 on NSE on October 16, 2026, down 0.29 percent from the INR 1,764.00 prior close.

Valuation sets the second marker

The trailing P/E stood at 34.89 on October 16, 2026, while market capitalization reached INR 4.2 trillion. The dividend yield was 0.91 percent, according to The Economic Times. These figures place valuation alongside the October reporting date rather than treating the daily move as a standalone signal.

Stock stays below the yearly high

The NSE session ranged from INR 1,743.50 to INR 1,764.90, with volume at 1,522,442 shares against an average of 1,835,173 shares. The 52-week range was INR 1,583.70 to INR 2,046.90 on October 16, 2026. The closing price stood 14.08 percent below the high and 11.05 percent above the low. Sun Pharma's year-to-date performance was 2.19 percent.

Peers show a mixed session

Sun Pharma: minus 0.29 percent, P/E 34.89, market capitalization INR 4.2 trillion
Cipla (NSE, INR): minus 0.22 percent, P/E 31.78, market capitalization INR 1.1 trillion
Dr. Reddy's Laboratories (NSE, INR): plus 1.17 percent, P/E 31.05, market capitalization INR 1.0 trillion

The next date is October 29

The next scheduled corporate date is October 29, 2026, for a board meeting concerning quarterly results, as listed by The Economic Times. The date gives the valuation figures a defined near-term reference point.

Trading range remains the key frame

Sun Pharma stock finished the NSE session below its 52-week high while remaining above the yearly low. The next scheduled results date and the 34.89 trailing P/E provide the clearest calendar and valuation markers for the stock report.